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Abstract 
It has previously been demonstrated that opiates interact directly with P-glycoprotein drug resistant Chinese hamster ovary (CHO) 
cells (Callaghan, R. and Riordan, J.R. (1993) J. Biol. Chem. 268, 16059-16064). In this study we have examined the effects of several 
opiates on the growth of drug sensitive and resistant CHO and human MCF7 cell lines. The growth of P-glycoprotein expressing ceils was 
inhibited by the opiates pentazocine, pethidine and naloxone to a greater extent han in drug sensitive cells. Since P-glycoprotein is
localised at the plasma membrane the effects of opiates on membrane biophysical properties were investigated. The opiates caused a 
fluidizing effect in membranes from P-glycoprotein expressing cells and decreased the basal evel of P-glycoprotein phosphorylation. I  
addition, they were able tc increase the leakage of the membrane impermeant compound 6-carboxyfluorescein trapped in model 
membrane vesicles. The ability to alter membrane biophysical properties correlated with the inhibitory effects on growth of drug resistant 
cells. These results uggest that the collateral sensitivity of P-glycoprotein expressing cell lines to opiates is mediated by the drugs' effects 
on the plasma membrane. 
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1. Introduction 
The phenomenon of multi-drug resistance has been 
widely investigated since it is a serious obstacle in the 
chemotherapeutic reatment of malignancies (reviewed in 
[1-3]). Resistant cells fi'equently overexpress a t80 kDa 
membrane glycoprotein, P-glycoprotein [4], which is widely 
believed to act as an ATP-dependant drug effiux pump [2]. 
The search for xenobiotics that reverse multi-drug resis- 
tance by competing with cytotoxic agents for transport by 
P-gp has been vigorous. Indeed several agents such as the 
calcium channel blockers [5], cyclosporin A [6], pheno- 
thiazines [7], anti-estrogens [8] and an antihistamine [9] 
have been shown to reverse multi-drug resistance. How- 
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ever, clinical trials with many reversing agents been lim- 
ited by toxicities of these agents [10,11]. More novel 
strategies for reversal of the MDR phenotype in vitro have 
been based on biochemical differences between sensitive 
and resistant cells. 
Several drug resistant cell lines display altered 
metabolism of high energy compounds such as ATP, ADP 
and phosphocreatine [12]. Furthermore, the antimetabolites 
sodium azide, deoxyglucose and lonidamine, an inhibitor 
of aerobic glycolysis, have been used to reverse MDR in 
vitro [13-15]. Another biochemical difference between 
drug sensitive and resistant cell lines is increased cytosolic 
pH in P-gp expressing cells [16]. MDR reversal agents 
such as verapamil are able to restore cytosolic pH levels to 
those in drug sensitive cells. Furthermore, it has recently 
been suggested that pH and/or ionic gradients across the 
plasma membrane of drug resistant cells directly generated 
by P-gp are responsible for the lower accumulation of 
cytotoxic drugs [17-19]. 
Certain growth conditions and substances have been 
demonstrated to be more toxic to MDR cells than drug 
sensitive parental lines ([20] for review). This phe- 
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nomenon, called hyper- or collateral sensitivity, in drug 
resistant cells has been demonstrated for verapamil [21], 
local anaesthetics [22], detergents [23], and long chain 
unsaturated fatty acids [24]. Interestingly, several com- 
pounds which cause collateral sensitivity are not substrates 
for binding or transport by P-glycoprotein and a mecha- 
nism of collateral sensitivity has not yet been elucidated. 
In this study we report hat drug resistant cells are collater- 
ally sensitive to several of the opiate class of narcotic 
analgesics. Furthermore, a correlation between their po- 
tency in causing hypersensitivity in resistant cells and 
ability to alter membrane biophysical properties has been 
established. 
2. Materials and methods 
2.1. Chemicals 
Morphine sulfate, naloxone hydrochloride, pethidine 
hydrochloride and pentazocine lactate were all purchased 
from The Hospital for Sick Children Pharmacy (Toronto, 
Ontario). [32p]Orthophosphate was obtained from Amer- 
sham (Ontario, Canada). Verapamil hydrochloride, dauno- 
mycin and adriamycin were purchased from Sigma (St. 
Louis, MO). Phosphatidylserine, phosphatidylcholine and 
phosphatidylethanolamine wer purchased from Avanti Po- 
lar Lipids. 6-Carboxyfluorescein was purchased from 
Molecular Probes (Eugene, OR). All other chemicals were 
obtained from regular suppliers and were of analytical 
grade. 
2.2. Tissue culture 
Drug sensitive Chinese hamster ovary cells (AuxB1) 
and the drug resistant line (B30) were grown in c~-mini- 
mum essential medium supplemented with 10% heat inac- 
tivated bovine serum, streptomycin (100 ng/ml) and peni- 
cillin (100 ng/ml) as previously described [21]. The resis- 
tant cells were maintained in medium containing colchicine 
(30 /~g~nl). The human breast carcinoma drug sensitive 
(MCF7~ and drug resistant (MCF7 Adr) cell lines were a 
generocis gift from Dr. Kenneth Cowan (NCI, Bethesda, 
M~I 'hese  cell lines were also grown in c~-minimum 
essential medium supplemented with 10% heat inactivated 
bovine serum, streptomycin (100 ng/ml) and penicillin 
(100 ng/ml) [25]. At each third passage the MCF7 Adr cell 
line was maintained in 3.8 /zg/ml adriamycin. 
2.3. P-glycoprotein detection 
The presence of P-glycoprotein B 1, B30, MCF7 and 
MCF7 adr cells was determined by Western blot analysis 
based on published methods [26]. Total cell protein was 
extracted in 1% SDS and 20/xg loaded on 6% SDS-PAGE 
gels. A micro-Lowry assay, using bovine serum albumin 
as a standard, was used to quantitate protein concentration. 
Proteins were electrophoretically transferred onto a nitro- 
cellulose filter and immunoblotting was performed using 
the anti-Pgp monoclonal antibody C219 (Centocor Diag- 
nostics). 
2.4. Cell cytotoxicity assay 
Cytotoxicity assays were based on previously published 
methods [21]. Briefly, cells from all lines were seeded in 
24-well tissue culture plates (Costar) at a density of 4000 
cells per well. Cells were allowed to adhere for 24 h at 
which time medium was supplemented with opiates in the 
concentration range of 5-150 /xM. The cells were left to 
grow for 7-10 days at which time medium was aspirated 
and cells washed four times with phosphate-buffered saline 
(PBS). Subsequently, the cells were fixed and stained for 
30 min in 50% methanol containing 5 g/1 methylene blue. 
Each well was extracted with 2 ml 1% (w/v)  SDS and the 
absorbance r ad at 650 nm. Cell survival was expressed as 
a percentage of absorbance obtained in the absence of 
drug. The IC50 dose for each drug was defined as the 
concentration at which the compound caused a 50% de- 
crease in cell growth. 
2.5. Liposomes containing 6-carboxyfluorescein 
Unilamellar liposomes composed of PC/PS /PE  (3:4:3) 
were made as follows. A film of phospholipid (10 mg total 
lipid) was prepared in glass tubes using reverse phase 
evaporation. 6-Carboxyfluorescein (50raM) was dissolved 
in 200 /zl l0 mM Tris-HCl (pH 8.3) and the pH of the 
final solution was adjusted to 7.4 with 1 M HCI. 6- 
Carboxyfluorescein is a hydrophilic ompound whose fluo- 
rescence is self-quenched atconcentrations of 50 mM and 
above [27]. The 6-CF (50 raM) containing solution was 
used to hydrate the lipid film and the suspension was 
subjected to 10 rounds of rapid freeze-thawing. At this 
stage the solution is composed of multi-lamellar phospho- 
lipid vesicles encapsulating 6-CF. The multi-lamellar vesi- 
cles were then passed through a 200 nm nitrocellulose 
filter (20-25 cycles) in a commercial extruder (Avestin, 
Ottawa) to generate uniform size unilamellar vesicles en- 
capsulating 6-CF. The liposome solution was subsequently 
passed through disposable PD-10 columns (Pharmacia, 
Uppsala) containing Sephadex G-25 media to remove un- 
encapsulated 6-CF. Fractions (1 ml) were collected and 
those containing loaded liposomes kept on ice for not more 
than 8 h. 
2.6. Effects of opiates on leakiness of model lipid bilayers 
Loaded liposomes (20/zl) were added to 2 ml of buffer 
composed of 10 mM Tris-HC1 (pH 7.4) and 150 mM 
NaCI. Fluorescence spectra of 6-carboxyfluorescein were 
recorded in a Hitachi 2000 fluorimeter with instrument 
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settings as follows; temperature 37 ° C, excitation wave- 
length 493 nm, emission wavelength 535 nm and both slit 
widths at 3 nm. Samples were stirred continuously and the 
reaction begun with the addition of drug. Total reaction 
time was 60 min at which point 50 /zl of 10% (w/v)  
Triton X-100 was added to disperse the liposomes and 
allow determination f total amount of fluorescence associ- 
ated with the encapsulated 6-CF. Results were plotted as 
the percentage of total flttorescence observed as a function 
of reaction time. The rate of leakage was determined from 
the initial slope of the fluorescence vs. time curves. The 
parameter EXT60 is defined as the amount of total fluo- 
rophore leaked from liposomes in the course of a 60 min 
incubation. 
2.7. Phosphorylation of P-gp in B30 cells 
The phosphorylation state of P-gp in B30 cells was 
determined using previously published methods [28]. 
Briefly, confluent monolayers of B30 cells (60 × 35 mm) 
were incubated with 300/xCi of [ 32 P]orthophosphate for 4 
h at 37°C in the presence of 100 /xM appropriate drug. 
Following the incubation period, cells were washed with 
PBS and harvested with 1 ml RIPA buffer (1% Triton 
X-100, 1% deoxycholate, 0.1% SDS, 150 mM NaC1, 20 
mM Tris-HCl pH 7.2). The cell extracts were incubated 
with anti-P-gp antibody for 15 h and subsequently for 2 h 
with protein A Sepharose as described [26]. Immobilised 
protein was eluted with 20 /zl Laemmli sample buffer at 
37°C for 15 min and subjected to SDS-PAGE elec- 
trophoresis using 8% gels (Novex Systems). Gels were 
dried and proteins visualised by autoradiography. 
2.8. Preparation of plasma membranes 
Plasma membranes fi'om B1 and B30 cells were pre- 
pared as previously described [29]. Membrane preparations 
were stored in 0.01 M Tris-HCl, pH 7.4, 0.25 M sucrose at 
- 70 ° C prior to use. Protein concentration was determined 
using a micro Lowry method. 
2.9. Lipid structural order in plasma membranes from B1 
and B30 cells 
centrifugation at 5000 × g for 5 min and spectra recorded 
on a Varian ESR machine. Spectral parameters were as 
follows; scan range 100 Gauss, field set 3175.4 Gauss, 
modulation amplitude 1.6 Gauss, scan time 4 rain at 
ambient temperature. Lipid structural order of plasma 
membranes in the presence/absence of drug was calcu- 
lated from the EPR spectra of 5-SASL as previously 
described [30]. 
3. Results 
3.1. Characterization of B1, B30, MCF7 and MCF7 Ad" 
cell lines 
Western blot analysis was used to demonstrate the 
levels of P-gp expressed in each cell line (Fig. 1). As 
expected no P-gp was detected in either of the drug 
sensitive parental lines, B 1 and MCF7 (lanes 1 and 3). In 
contrast, both drug resistant cell lines (B30 and MCF7 Adr) 
expressed P-gp at considerable vels (lanes 2 and 4). The 
amount expressed, per mg of total cell protein, was consid- 
erably higher in B30 cells. Cytotoxicity assays were per- 
formed to examine the relative levels of resistance to 
colchicine in the B30 and MCF7 Adr cell lines. The IC50 
dose of colchicine in B 1 cells was 33 ___ 16 nM as com- 
pared with 26.8 + 3.4/xM in B30 cells. This represents an 
820-fold increase in resistance to colchicine. In drug sensi- 
tive MCF7 cells the IC50 dose of colchicine was 1.9 ___ 0.9 
nM compared to 423 ___ 48 nM in the resistant MCF7 Adr 
cell lines. This difference represents a 220-fold resistance 
to colchicine in MCF7 Adr cells. Therefore, increased resis- 
tance of B30 compared to MCF7 Adr cells was in qualita- 
tive agreement with the higher expression of P-gp based 
on Western blot analysis. 
200 kDa 
The effects of opiates on lipid structural order in plasma 
membranes from B1 and B30 cells was determined by the 
electron paramagnetic resonance (EPR) spectra of 5- 
doxyl-stearic acid (5-SASL). Membranes (350 /xg) were 
pelleted (150000 × g) using an Airfuge (Beckman Instru- 
ments), washed in buffer and aliquoted (50/zg) into 25/zl 
sucrose buffer containing 5-SASL and drug. The mem- 
brane-drug mixtures were left to stand for 20 rain at room 
temperature, centrifuged as above, and washed five times 
to remove unincorporated probe. The mixture was then 
drawn into 50 /zl capacity capillary tubes which were 
subsequently flame sealed. Membranes were pelleted by 
97 kDa 
69 kDa 
q 
1 2 3 4 
Fig. 1. Western blot analysis of P-gp expression i B1 (lane 1), B30 (lane 
2), MCF7 (lane 3) and MCF7 Adr (lane 4) cell lines. All lanes were loaded 
with 20/xg cell protein and the blot probed with the monoclonal ntibody 
C219. 
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Fig. 3. Growth inhibitory effects of pentazocine (top left), naloxone (top right), pethidine (bottom left) and morphine (bottom right) on MCF7 (O) and 
MCF7 Adr ( [] ) cell lines. Cells were seeded at approx. 4000 per well at drug concentration i dicated, Results shown are mean (+ S.E.) of three independent 
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3.2. Effects of opiates on growth of B1, B30, MCF7 and 
MCF7 Ad~ cell lines 
The effects of naloxone, pentazocine, pethidine and 
morphine on the growth of drug sensitive (B1) and drug 
resistant (B30) cell line:~ is shown in Fig. 2. Naloxone 
caused a 50% reduction in growth of B 1 cells at a concen- 
tration of 85 /zM (IC50). However, in B30 cells the IC50 
for naloxone was 27 /xM which is a 3.2-fold increase in 
sensitivity. Neither penlazocine nor pethidine caused a 
reduction in growth of drug sensitive B 1 cells at concentra- 
tions up to 100 /zM. In contrast, both drugs caused 
significant reductions in growth of drug resistant B30 cells. 
The respective IC50 values for pentazocine and pethidine 
were 22 /zM and 42 /zM[ which indicate significant hyper- 
sensitivity of B30 cells to these drugs. However, morphine 
did not have any effects on growth of B1 or B30 cells at 
concentrations up to 12C~ /zM. Thus, the narcotic agonists 
pentazocine, pethidine and the narcotic antagonist nalox- 
one, were able to cause raarked reductions in the growth of 
drug resistant B30 cells compared to parental cells. 
The above effects were observed in CHO cell lines 
which highly overexpress P-glycoprotein. As described 
above, MCF7 Adr cells have significantly less P-gp and are 
less resistant o colchicine than B30 cells. Therefore, the 
experiments on cell growth were repeated in drug sensitive 
and resistant human breast cancer cell lines to determine if
the collateral sensitivity to opiates was dependant on P-gp 
levels and degree of resistance. The effects of opiates on 
cell growth of drug sensitive and resistant cell lines are 
shown in Fig. 3. Morphine did not affect the growth of the 
drug sensitive MCF7 cell line but impaired the growth of 
drug resistant MCF7 ha' cells. However, the growth in- 
hibitory effects on MCF7 Aar cells was not large and the 
effects only occurred at concentrations of morphine greater 
then approx. 100 /zM. Naloxone was the only compound 
found to inhibit the growth of drug sensitive MCF7 cells. 
The IC50 value for naloxone is 90 /zM which is similar to 
effects on drug sensitiw~ B 1 cells. Pentazocine and pethi- 
dine did not cause any growth inhibitory effects in MCF7 
cells at concentrations up to 150 /zM. However, drug 
Table 1 
The effects of morphine, naloxone, pethidine, pentazocine and verapamil 
on lipid structural order in plasma membranes from drug sensitive (B1) 
and drug resistant (B30) cells 
Compound B 1 B30 
Control 0.495 + 0.003 0.501 ___ 0.007 
Morphine 0.474 + 0.021 0.485 + 0.001 
Naloxone 0.476 _+ 0.003 a 0.488 + 0.007 
Pethidine 0.487 _+ 0.010 0.487 + 0.015 
Pentazocine 0.482 + 0.018 0.478 + 0.004 a 
Verapamil 0.496 + 0.009 0.465 _+ 0.007 a 
All values were obtained from three independent experiments and are 
expressed asmean -t- S.E. 
a Statistically significant difference from the control value in the same 
cell line ( P < 0.05), 
resistant MCF7 adr cells remained hypersensitive to penta- 
zocine, pethidine and naloxone. The respective IC50 values 
were 80 /zM, 120 /xM and 30 ~M. Thus the narcotic 
agonists pethidine, pentazocine and the narcotic antagonist 
naloxone were also able to inhibit preferentially, the growth 
of drug resistant MCF7 Adr cells. However, the IC50 con- 
centrations were higher than observed in drug resistant 
B30 cells. Therefore, it appears that the susceptibility of 
drug resistant cell lines to the growth inhibitory effects of 
opiates correlates with the degree of resistance and amount 
of P-gp expressed in the respective cell lines (see Fig. 2). 
3.3. Opiate induced alterations in lipid structural order in 
B1 and B30 plasma membranes 
Lipid structural order was investigated using the 
lipophilic probe 5-SASL which has previously been 
demonstrated to localise at the plasma membrane [31]. 
Table 1 shows the effects of opiates and verapamil on the 
structural order of 5-doxyl-stearic acid in plasma mem- 
branes from drug sensitive and resistant CHO cells. Vera- 
pamil was included since it has been previously estab- 
lished as a potent collateral sensitizing agent in B30 cells 
[32]. There was no significant difference in gross plasma 
membrane lipid structural order between B 1 and B30 cells 
which is in agreement with previous reports [20]. Vera- 
pamil and opiate analgesics were unable to alter structural 
order to statistically significant levels in drug sensitive 
cells. Naloxone, an opiate antagonist reduced structural 
order in plasma membranes from B1 cells and was the 
only compound tested to cause significant inhibition of 
drug sensitive cell growth. Verapamil and the opiate penta- 
zocine both caused statistically significant reductions in 
lipid structural order in plasma membranes from B30 cells. 
These two compounds are potent agents in causing collat- 
eral sensitivity of drug resistant B30 cells. A decrease in 
lipid structural order, also referred to as membrane fluid- 
ity, indicates increased motion by the acyl chains of mem- 
brane lipids [33]. Naloxone and pethidine caused smaller 
reductions in lipid structural order, however, the reductions 
did not reach statistical significance. Nonetheless, there 
appears to be a correlation between potency in causing 
growth inhibition of drug resistant cells and effects of 
drugs on plasma membrane lipid structural order. These 
results may suggest hat the expression of P-gp renders 
membranes more susceptible to gross changes in fluidity 
when exposed to verapamil and some opiate analogues. 
3.4. Leakiness of PC / PS /  PE unilamellar vesicles 
The ability of opiates to induce leakage of the hy- 
drophillic fluorescent dye 6-CF trapped inside unilamellar 
vesicles is shown in Fig. 4. The effect was immediate and 
had not reached a plateau at 60 min after addition of drug. 
The initial rate and the extent of leakage after 60 min 
(EXT6o), from liposomes was determined for each drug at 
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Fig. 4. Effects of several compounds on the leakage of 6-CF entrapped in
unilamellar vesicles composed of PC/PS/PE (3:4:3). Values plotted 
expressed as the % of total fluorescence observed as a function of 
reaction time. All drug concentrations were 0.4 mM. Values are the mean 
(5: S.E.) obtained from three independent experiments. (Meperidine is a 
synonym for pethidine.) 
three concentrations and the data summarized in Table 2. 
In the absence of any drug the rate of 6-CF leakage from 
liposomes was almost negligible with less than 3% of total 
entrapped 6-CF leaking after 60 min incubation. Vera- 
pamil, pentazocine, pethidine and naloxone, were able to 
significantly increase both the rate and EXT60 above the 
levels obtained in the absence of drug at all concentrations 
examined. The increases in rate and EXT60 occurred in a 
dose-dependant manner with verapamil and pentazocine 
Table 2 
The effect of opiates on the leakage of 6-carboxyfluorescein from 
PC/PS/PE (3:4:3) unilamellar liposomes at 37 ° C 
Initial rate (%/min) EXT6o (% total) 
Control 0.048 + 0.010 2.7 _ 0.4 
Morphine 
100 p,M 0.039+0.006 3.4+0.3 
200/zM 0.055+0.011 3.7+0.2 
400/zM 0.070 + 0.005 3.5 -F 0.1 
Pethidine 
100 tzM 0.131 +0.023 a 6.9___0.8 a 
200/zM 0.189+0.024 a 8.7+ 1.0 a 
400 tzM 0.215+0.043 a 10.2+ 1.9 a 
Naloxone 
100/xM 0.130+0.030 a 4.4+ 1.6 
200/xM 0.160 + 0.050 a 7.8 _ 3.2 a 
400/xM 0.320+0.050 a 13.3+0.4 a
Pentazocine 
100/zM 0.177+0.026 a 9.1 + 1.2 a 
200/zM 0.314+0.040 a 15.3-t- 1.7 a 
400/xM 0.634+0.051 a 29.1 +2.3 ~ 
Verapamil 
100/zM 0.2605:0.010 a 12.95:1.2 ~ 
200/zM 0.6205:0.040 a 24.0+ 1.6 a 
400 IxM 1.5205:0.120 a 58.35:2.2 ~ 
Excitation wavelength 493 nm and emission wavelength 535 rim. 
a Values significantly different from control data (P < 0.05). 
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Fig. 5. The effects of several drugs on the phosphorylation state of P-gp 
in drug resistant B30 cells. Cells were labelled with [32 P]ortbophosphate 
for 4 hours as described in Materials and methods. P-gp has a basal state 
of phosphorylation (lane 1). The effects of several compounds on the 
basal level of phosphorylation was examined: (lane 2) naloxone, (lane 3) 
morphine, (lane 4) pentazocine, (lane 5) pethidine and (lane 6) verapamil. 
the most potent permeabilizing agents, leading to increases 
in the initial rate of 6-CF leakage by 5.4 and 3.7-fold 
respectively at 100 /xM concentrations. These two com- 
pounds also caused the most marked changes in drug 
resistant plasma membrane fluidity and pentazocine was 
the most potent opiate collateral sensitizer. Pethidine and 
naloxone xhibited intermediate potency in 6-CF leakage 
while morphine did not significantly affect permeability at 
any of the concentrations examined. Morphine also did not 
significantly alter membrane fluidity or confer collateral 
sensitivity to B30 cells. Ability to induce leakage of the 
hydrophilic ompound 6-CF entrapped in model iposomes 
represents significant alteration of membrane biophysical 
properties. The order of potency in causing leakage of 
6-CF from model ipids by opiates correlates well with the 
respective ability of these drugs to confer collateral sensi- 
tivity in resistant B30 and MCF7 Aar cells. 
3.5. Modification of P-gp phosphorylation by opiates 
Agents which confer collateral sensitivity have been 
demonstrated to increase the basal phosphorylation state of 
P-gp [34]. Drug resistant B30 cells were labelled with 
[32 P]orthophosphate in the presence or absence of drug for 
4 h and P-gp was subsequently immunoprecipitated and 
subjected to electrophoresis. The results are shown in Fig. 
5. In the control lane a band corresponding to P-gp was 
observed at 180 kDa. This basal evel of P-gp phosphoryla- 
tion has previously been demonstrated [28]. Incubation 
with verapamil did not significantly alter the phosphoryla- 
tion state of P-gp, which is in contrast o the effects seen 
with opiates. All opiates tested were able to significantly 
reduce the phosphorylation f P-gp and the order of po- 
tency was naloxone > morphine > pentazocine > pethidine 
as determined by densitometric analysis. Whole cell lysates 
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following metabolic labelling with [32p]orthophosphate 
were subjected to SDS-polyacrylamide g l electrophoresis 
and autoradiography. There was no significant effect of 
any opiate on total protein phosphorylation state (data not 
shown). This indicates that the effects of opiates on phos- 
phorylation were not due to non-specific effects such as 
ATP-depletion. The ability of opiates to alter the phospho- 
rylation state of P-gp did not, however, correlate precisely 
with the growth inhibition potency shown in Fig. 2. Alter- 
ation of membrane biophysical properties has been shown 
to modify the activity of protein kinase C, which is known 
to phosphorylate P-gp [35]. 
4. Discussion 
The phenomenon of collateral or hypersensitivity was 
first described by Bech-Itansen i 1976 [23] and since then 
several compounds have been shown to cause growth 
inhibition of drug resistant cells [36]. In the present study 
we have demonstrated t!aat several opiate analogues were 
able to inhibit the growth of drug resistant cells at much 
lower doses than in drug sensitive parental lines. Opiates 
have also recently been shown to inhibit the binding and 
transport of vinca alkaloids by P-glycoprotein in drug 
resistant cells [37]. Verapamil, which is a very strong 
inducer of collateral sensitivity [32], also inhibits cytotoxic 
drug binding to P-gp [5]. The growth inhibition of drug 
resistant cells to opiates in the present study appeared to be 
a function of the relative resistance and amount of P-gp 
present. A similar relationship between level resistance to 
cytotoxicity and hypersensitivity to a series of detergent 
compounds has been described [23]. Therefore, it appears 
that P-gp expression has a major role in rendering cells 
vulnerable to collateral sensitizing agents. 
However, many collateral sensitivity agents such as 
local anaesthetics, detergents and fatty acids do not appear 
to act directly on P-gp 1136]. The common property shared 
by collateral sensitizers i  their ability to alter membrane 
biophysical properties [:22-24,36] suggesting that toxicity 
is mediated at the plasma membrane l vel. Several reports 
have described a number of alterations to plasma mem- 
brane biophysical properties in resistant cells compared to 
parental cells [20,38]. Specifically, increased fragility to 
shear forces, elevated rates of endocytosis, a decreased 
surface hydrophobicity and an increased intramembranous 
particle density have been described in various drug resis- 
tant cell lines [38-40]. The absence of gross differences in
lipid composition between drug resistant and sensitive 
cells suggests that expression of P-gp is responsible for the 
altered membrane properties [38,39]. In turn, several com- 
pounds and growth conditions which alter membrane bio- 
physical properties are able to reverse MDR and/or confer 
collateral sensitivity [24,38,41]. 
In this study the potent collateral sensitizer verapamil 
and several of the opiates altered membrane biophysical 
properties uch as increased membrane fluidity to varying 
degrees in drug resistant cells. Bulk phase fluidity de- 
scribes the motion of membrane phospholipid acyl chains 
[33] and alterations in plasma membrane fluidity have 
previously been shown to alter P-gp dependant drug trans- 
port [41,42]. Verapamil and the opiates investigated in this 
study are hydrophobic molecules that would be expected 
to cause disruption of phospholipid movement upon inter- 
calation into lipid bilayers. The increased alteration of 
fluidity in drug resistant cell membranes compared to 
membranes from parental cells may reflect the inherent 
instability of bilayers containing P-gp [38-40]. Modifica- 
tion of membrane lipid structural order, or fluidity, may 
also lead to altered permeability properties of plasma 
membranes. Indeed, opiates and verapamil were shown to 
affect the lipid bilayer of model liposomes ufficiently to 
allow passage of an entrapped polar fluorescent dye, 6-CF. 
Several drugs and hydrophobic compounds which disrupt 
phospholipid packing in bilayers have also been demon- 
strated to increase membrane permeability [43,48]. In the 
present study, the ability of opiates to increase membrane 
permeability o 6-CF correlated well with the drugs collat- 
eral sensitization potency. Furthermore, other collateral 
sensitizing agents have been shown to increase membrane 
permeability in non-Pgp expressing cells [21] suggesting 
an effect on the membrane lipid phase. As mentioned 
earlier several reports have indicated that the expression of 
P-gp leads to severe alterations in plasma membrane bio- 
physical properties [38-40] resulting in a more unstable or 
less rigid membrane. Consequently, further disruption of 
plasma membrane biophysical properties uch as fluidity 
and permeability by opiates may have consequences for 
drug resistant cell viability. 
Opiates were also shown to reduce the basal phospho- 
rylation state of P-gp. Phosphorylation f P-gp has been 
shown to control specificity and influence the activity of 
drug transport [47]. It has also been demonstrated that 
administration of trifluoperazine and N-ethylmaleimide 
lead to hyperphosphorylation of P-gp in drug resistant cells 
[34]. In the same study it was postulated that the hyper- 
phosphorylation f P-gp by trifluoperazine and N-ethyl- 
maleimide resulted in collateral sensitivity of drug resistant 
cells to these agents [34]. P-gp is phosphorylated by pro- 
tein kinase C [44,45] whose activity is controlled by 
calcium and membrane biophysical properties [46]. Several 
compounds which affect membrane biophysical properties 
have been shown to alter PKC activity ([46] for review). In 
the present study although we have not shown a direct 
correlation between changes in P-gp phosphorylation a d 
collateral sensitivity, a link cannot be entirely ruled out. 
What is clear is that opiates are able to modify membrane 
biophysical properties. This alteration i  membrane charac- 
teristics may modify the activity of PKC, an enzyme 
playing a major role in phosphorylation f P-gp. However, 
the consequences of decreased P-gp phosphorylation by 
opiates for cell viability is not clear. 
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In summary, the present study demonstrates that opiates 
induce collateral sensitivity in drug resistant cells express- 
ing P-gp. The degree of hypersensitivity appears to be 
proportional to the amount of P-gp and the mechanism 
related to the membrane perturbing properties of opiates. 
Several investigations indicate that the membranes of drug 
resistant cells are less stable. Therefore, the membrane 
perturbing effects of opiates and verapamil may prefer- 
entially target drug resistant cells, thus compromising cell 
integrity and consequently cell viability. 
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